GlassScriptPhysician profile
Yasmin Bilal
NPI 1699932061
$2,088.60
in general payments reported to CMS, 2019-2025
19 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.39 · 2021: $319 · 2022: $167 · 2023: $595 · 2024: $672 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,572.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $747.08 | 2021-2024 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $375.65 | 2023-2024 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $185.82 | 2022-2023 | Xarelto |
| Abiomed | $136.36 | 2021 | |
| Lilly USA, LLC | $124.99 | 2023 | Mounjaro |
| Pfizer INC. | $70.13 | 2024-2025 | |
| Janssen Biotech, INC. | $67.97 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $64.93 | 2023-2025 | Sotyktu, Camzyos |
| Abbvie INC. | $61.72 | 2021-2023 | Dalvance |
| Ani Pharmaceuticals, INC. | $53.30 | 2025 | Purified Cortrophin Gel, Sovuna |
| Amgen INC. | $51.08 | 2025 | Evenity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.88 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.39 | 2025 | Strensiq |
| Merck Sharp & Dohme LLC | $17.93 | 2023 | Zerbaxa, Dificid, Recarbrio |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $17.06 | 2019 | |
| Boston Scientific Corporation | $16.88 | 2022 | |
| Gilead Sciences, INC. | $15.45 | 2024 | |
| Allergan, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasmin Bilal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.